<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17697" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Antihypertensive Medications</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khalil</surname>
            <given-names>Hassan</given-names>
          </name>
          <aff>The George Washington University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zeltser</surname>
            <given-names>Roman</given-names>
          </name>
          <aff>Hofstra Northwell School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hassan Khalil declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Roman Zeltser declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17697.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Hypertension (HTN) is considered one of the leading causes of increased cardiovascular disease. Lowering blood pressure does reduce cardiovascular risks; maintaining systolic blood pressure of less than 130 mm Hg demonstrably prevents complications in patients with heart failure, diabetes, coronary artery disease, stroke, and other cardiovascular diseases. This activity discusses the guidelines for selecting the appropriate antihypertensive medications. It presents the different classes for first, second, and third-line treatments for hypertension and highlights the indications and side effects. It highlights the studies done to compare different classes of antihypertensive medications and indications for each class.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the guidelines for using antihypertensive medications and guide the treatment choices for first-line treatment.</p></list-item><list-item><p>Review the different anti-hypertensive medication classes, summarizing the guidelines for the indication to use combination treatment when mono-therapy fails.</p></list-item><list-item><p>Outline the significant side effects of each class of antihypertensive medications.</p></list-item><list-item><p>Identify the approach of the interprofessional team to identify an appropriate care plan for a hypertension patient.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17697&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17697">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17697.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Hypertension (HTN) is considered one of the leading causes of increased cardiovascular disease.</p>
        <p>The 2017 American College of Cardiology (ACC) and American Heart Association (AHA) definition of HTN stages is:</p>
        <list list-type="bullet">
          <list-item>
            <p>Normal blood pressure (BP): systolic BP is less than 120, and diastolic BP is less than 80.</p>
          </list-item>
          <list-item>
            <p>Elevated BP: systolic BP is 120&#x000a0;to 130, and diastolic BP is less than 80.</p>
          </list-item>
          <list-item>
            <p>Stage 1 HTN: systolic BP 130&#x000a0;to 139 or diastolic BP 80&#x000a0;to 89.</p>
          </list-item>
          <list-item>
            <p>Stage 2 HTN: systolic BP at least 140 or diastolic at least 90.</p>
          </list-item>
          <list-item>
            <p>Hypertensive crises: systolic BP over 180 and/or diastolic BP over 120.</p>
          </list-item>
        </list>
        <p>In the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, all patients with elevated blood pressure are recommended to have lifestyle modifications as initial treatment, including weight loss, a healthy heart diet, increased physical activity, a low sodium diet, and limitation of alcohol consumption.</p>
        <list list-type="bullet">
          <list-item>
            <p>In patients with stage 1 HTN, recommendations are to start antihypertensive medications if the patient has a 10-year ASCVD risk of 10% or higher with a target of BP less than 130/80 to prevent patients from cardiovascular events. The recommendation is for patients with stage 1 HTN and a 10-year ASCVD risk of less than 10% to have lifestyle modification measures.</p>
          </list-item>
          <list-item>
            <p>All patients with stage 2 HTN should start antihypertensive medications to lower BP to a target lower than 130/80 mm Hg, even if the 10-year ASCVD risk is less than 10%.</p>
          </list-item>
          <list-item>
            <p>In patients with chronic kidney disease, the target BP is 130/80</p>
          </list-item>
          <list-item>
            <p>For patients with type 2 diabetes mellitus (T2DM), it is recommended to start on antihypertensive medications if BP is more than 130/80 mm Hg with a goal of BP lower than 130/80 mm Hg.</p>
          </list-item>
          <list-item>
            <p>Antihypertensive medication treatment usually starts as monotherapy after the failure of conservative management with lifestyle modification. The use of combination therapy is common when patients fail the monotherapy approach.</p>
          </list-item>
          <list-item>
            <p>Lowering blood pressure does reduce cardiovascular risks; maintaining a systolic blood pressure of less than 130 mm Hg has been shown to prevent complications in patients with heart failure, diabetes, coronary artery disease, stroke, and other cardiovascular diseases.<xref ref-type="bibr" rid="article-17697.r1">[1]</xref>&#x000a0;The response to initial monotherapy is affected by age and race.</p>
          </list-item>
        </list>
        <p>There are multiple classes of antihypertensive medications used for the treatment of HTN; the most recommended classes used as first-line for treatment are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Thiazide-type diuretics</p>
          </list-item>
          <list-item>
            <p>Calcium channel blockers</p>
          </list-item>
          <list-item>
            <p>Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs)</p>
          </list-item>
        </list>
        <p>
<bold>Thiazide Diuretics&#x000a0;</bold>
</p>
        <p>Thiazide and thiazide-like diuretics are usually the first line of treatment for hypertension; in JNC8 guidelines, the thiazide diuretics can be used as the first-line treatment for HTN (either alone or in combination with other antihypertensives) in all age groups regardless of race unless the patient has evidence of chronic kidney disease where angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker is indicated.<xref ref-type="bibr" rid="article-17697.r2">[2]</xref></p>
        <p>The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study recommended thiazide diuretics as the first line of treatment for hypertension unless there are contraindications.</p>
        <p>Treatment with hydrochlorothiazide as a single agent with a dose of 12.5 mg or 25 mg daily showed no evidence of decreasing morbidity or mortality.<xref ref-type="bibr" rid="article-17697.r3">[3]</xref></p>
        <p>Research shows that thiazide-type diuretics (chlorthalidone and indapamide)&#x000a0;are&#x000a0;superior in preventing cardiovascular disease at a lower cost. Recommendations are to start them as first-line treatment for hypertension. Multiple studies have shown that thiazide-like diuretics (chlorthalidone and indapamide) in hypertension treatment are more potent than hydrochlorothiazide. They are better at decreasing the risk of cardiovascular disease compared to hydrochlorothiazide.<xref ref-type="bibr" rid="article-17697.r4">[4]</xref><xref ref-type="bibr" rid="article-17697.r5">[5]</xref></p>
        <p>Chlorthalidone is the drug of choice to start as monotherapy for hypertension. Studies show it to be the best diuretic to control blood pressure and prevent mortality and morbidity.<xref ref-type="bibr" rid="article-17697.r6">[6]</xref><xref ref-type="bibr" rid="article-17697.r7">[7]</xref>&#x000a0;It demonstrated greater effectiveness than hydrochlorothiazide in lowering blood pressure when researchers monitored 24-hour ambulatory blood pressure.<xref ref-type="bibr" rid="article-17697.r4">[4]</xref>&#x000a0;Hydrochlorothiazide has a shorter effect during the day in a study that compared the office blood pressure reading with the 24-hour ambulatory blood pressure readings.<xref ref-type="bibr" rid="article-17697.r8">[8]</xref>&#x000a0;Switching to chlorthalidone from hydrochlorothiazide decreases systolic blood pressure by 7&#x000a0;to 8 mm Hg.<xref ref-type="bibr" rid="article-17697.r9">[9]</xref></p>
        <p>The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) showed that chlorthalidone at 12.5 to 25 mg/day caused fewer cardiovascular complications than amlodipine and lisinopril.</p>
        <p>Chlorthalidone is the first choice for older patients with osteoporosis, as it&#x000a0;was associated with a lower incidence of pelvic fractures when compared to amlodipine and lisinopril.<xref ref-type="bibr" rid="article-17697.r10">[10]</xref>&#x000a0;Compared with doxazosin mesylate and lisinopril, chlorthalidone was better in preventing cardiovascular disease, including strokes and incidence, and when compared with amlodipine, it was better in preventing heart failure.<xref ref-type="bibr" rid="article-17697.r11">[11]</xref></p>
        <p>
<bold>Calcium Channel Blockers CCBs</bold>
</p>
        <p>Same as thiazide-type diuretics, CCBs are recommended in JNC8 guidelines to be used as a first-line treatment alone or in combination with other antihypertensives in all patients with HTN regardless of age and race, except for patients with chronic kidney disease&#x000a0;where ACE inhibitors or ARBs are the recommended first-line treatment.<xref ref-type="bibr" rid="article-17697.r2">[2]</xref></p>
        <p>CCBs&#x000a0;have been shown to decrease all cardiovascular events other than heart failure, similar to thiazide diuretics. They can be used as the best alternative to thiazides when patients do not tolerate thiazides.<xref ref-type="bibr" rid="article-17697.r6">[6]</xref></p>
        <p>CCBs divide into two groups: dihydropyridines and non-dihydropyridines</p>
        <p>Dihydropyridines are more potent as vasodilators and are used more for HTN treatment. They have less effect on heart contractility and conduction. For this, they are used more for the management of HTN. Nifedipine and amlodipine are the most used medications in this group.</p>
        <p>Non-dihydropyridines are less potent as vasodilators and have a better effect on cardiac contractility and conduction. They are used more as antiarrhythmic medications and less for HTN treatment.</p>
        <p>For African descent patients, initial treatment for hypertension (without evidence of heart failure or chronic kidney disease) should include CCB or a thiazide diuretic.<xref ref-type="bibr" rid="article-17697.r6">[6]</xref></p>
        <p>Long-acting nifedipine has greater antihypertensive action when compared to amlodipine.<xref ref-type="bibr" rid="article-17697.r9">[9]</xref></p>
        <p>Dihydropyridines should not be a primary treatment for congestive heart failure (CHF) but&#x000a0;represent a safe additional treatment in these patients for better blood pressure control or angina pectoris.</p>
        <p>Non-dihydropyridines are relatively contraindicated in patients with CHF with reduced ejection fraction, second and third-degree heart blocks, and in patients with sick sinus syndrome.</p>
        <p>Compared to valsartan in a study, amlodipine was found to have better control of 24-hour ambulatory blood pressure. In the ASCOT trial, amlodipine was found to be better than atenolol in lowering the risk of cardiovascular disease and is associated with less risk of diabetes development.<xref ref-type="bibr" rid="article-17697.r12">[12]</xref>&#x000a0;Compared to thiazide diuretics, amlodipine was equally effective in reducing cardiovascular disease risk regardless of the patient's weight, while thiazides are less effective in normal body mass index (BMI) patients than in patients with obesity.<xref ref-type="bibr" rid="article-17697.r13">[13]</xref></p>
        <p>
<bold>ACE Inhibitors and ARBs</bold>
</p>
        <p>ACE inhibitors and ARBs are the antihypertensives of choice for patients with heart failure and chronic kidney disease. They are indicated as first-line treatment for patients with chronic kidney disease with evidence of proteinuria. JNC8 guidelines list these two classes of antihypertensive medications as first-line treatment for HTN for non-black patients, along with thiazides and CCBs.<xref ref-type="bibr" rid="article-17697.r2">[2]</xref></p>
        <p>Independent of their antihypertensive effect, they are proven to have a cardioprotective effect in patients with a high risk of cardiovascular disease.</p>
        <p>Both classes have similar efficacy and share the same indications for treatment; they are both recommended as first-line treatment for patients with left ventricular dysfunction and ST-elevation MI or non-ST elevation MI with the presence of diabetes, systolic dysfunction, or anterior infarct.&#x000a0;</p>
        <p>Thiazide is better than ACE inhibitors in decreasing blood pressure and preventing stroke; CCBs are better than ACE inhibitors in lowering blood pressure and preventing stroke and heart failure.<xref ref-type="bibr" rid="article-17697.r6">[6]</xref></p>
        <p>Ramipril has been shown to decrease mortality, the incidence of stroke, and MIs when used in patients with symptomatic heart failure or asymptomatic patients with low ejection fraction. The research found perindopril decreases cardiovascular events when used in a patient with stable coronary artery disease and normal systolic dysfunction. Compared with atenolol, losartan was found to be better in reducing morbidity and mortality and better in lowering blood pressure.</p>
        <p>Comparing ramipril with telmisartan, they were equivalent in effect in diabetic or heart failure patients, with telmisartan&#x000a0;showing a correlation with less angioedema.<xref ref-type="bibr" rid="article-17697.r14">[14]</xref></p>
        <p><bold>Beta-Blockers</bold>&#x000a0;&#x000a0;</p>
        <p>Beta-blockers are not indicated as primary treatment for hypertension unless there is a specific indication of heart failure and myocardial infarction.<xref ref-type="bibr" rid="article-17697.r15">[15]</xref></p>
        <p>Beta-blockers are associated with decreased cardiovascular morbidity and mortality when used in younger patients but are less protective in patients older than 65&#x000a0;and were noted to be associated with an increased risk of strokes.<xref ref-type="bibr" rid="article-17697.r15">[15]</xref><xref ref-type="bibr" rid="article-17697.r16">[16]</xref><xref ref-type="bibr" rid="article-17697.r17">[17]</xref></p>
        <p>
<bold>Combination Therapy</bold>
</p>
        <p>When a patient fails a monotherapy for HTN, a combination should merit consideration. Combining&#x000a0;two antihypertensive medications should be a therapeutic option for patients with stage 2 hypertension.<xref ref-type="bibr" rid="article-17697.r6">[6]</xref>&#x000a0;One study showed&#x000a0;the reduction in blood pressure when drugs from two different classes are combined is approximately five times greater than when the dose of one drug dose doubles.<xref ref-type="bibr" rid="article-17697.r18">[18]</xref></p>
        <p>A combination of ARB-diuretic or ACE inhibitor-CBB is superior to the beta-blocker-diuretic combination.<xref ref-type="bibr" rid="article-17697.r19">[19]</xref>&#x000a0;The beta-blocker and diuretic combination is associated with a higher incidence of diabetes. Clinicians should use combinations containing beta-blockers when beta-blockers are indicated in patients with heart failure, tachycardia, or post-MI patients. A combination of thiazide with a potassium-sparing diuretic is as effective as CCB monotherapy in HTN management and showed less incidence of hypokalemia when compared to hydrochlorothiazide monotherapy&#x000a0;<xref ref-type="bibr" rid="article-17697.r19">[19]</xref></p>
        <p>Combination formulations of CCB and diuretics are&#x000a0;not as common;&#x000a0;ARBs or ACE inhibitor-based combinations are preferred when a combination is required. These types of combinations (ACE inhibitors or ARB-based combinations) should be used in patients with CKD.<xref ref-type="bibr" rid="article-17697.r19">[19]</xref><xref ref-type="bibr" rid="article-17697.r20">[20]</xref></p>
        <p>The combination of benazepril-amlodipine is superior to the benazepril-hydrochlorothiazide combination in decreasing the incidence of cardiovascular events in patients with high risk,&#x000a0;and it decreases the progression of nephropathy.<xref ref-type="bibr" rid="article-17697.r21">[21]</xref><xref ref-type="bibr" rid="article-17697.r22">[22]</xref></p>
        <p>The ACE inhibitor-ARB combination is not recommended; it showed a higher incidence of side effects with no added benefits.<xref ref-type="bibr" rid="article-17697.r14">[14]</xref><xref ref-type="bibr" rid="article-17697.r23">[23]</xref></p>
        <p>When the combination of 2 medications does not achieve the treatment goal, a third agent should be added, usually done by adding a third agent of the first line group of drugs (thiazide-like diuretics, CCB, ACE inhibitors, and ARBs).</p>
        <p>When the patient fails the three-drug regimen, the clinician should consider treatment for resistant HTN, adding a fourth antihypertensive agent from any other classes.<xref ref-type="bibr" rid="article-17697.r19">[19]</xref></p>
        <p><bold>Loop diuretics</bold>&#x000a0;are more effective than thiazides in patients with a low estimated glomerular filtration rate&#x000a0;of less than 30 mL/min. They have been approved to treat peripheral edema associated with congestive heart failure and other noncardiac causes of edema, as in liver and kidney diseases.<xref ref-type="bibr" rid="article-17697.r24">[24]</xref>&#x000a0;Loop diuretics are not the first-line agents for HTN treatment.<xref ref-type="bibr" rid="article-17697.r25">[25]</xref></p>
        <p><bold>Potassium Sparing Diuretics: "Mineralocorticoid receptor antagonists"&#x000a0;</bold>are not usually used as first-line treatment. Spironolactone and eplerenone are considered good in hypertension treatment when added to other antihypertensive medications in resistant HTN; this group of medications is effective when added to triple hypertension medications regimen but should be used cautiously when added to ACE inhibitors or ARBs due to the higher incidence of hyperkalemia.<xref ref-type="bibr" rid="article-17697.r26">[26]</xref><xref ref-type="bibr" rid="article-17697.r27">[27]</xref>&#x000a0;They effectively treat heart failure as they are proven to decrease mortality rates and help decrease hypokalemia rates. Spironolactone is superior to doxazosin and bisoprolol in lowering blood pressure when added to first-line antihypertensive agents in treating resistant hypertension.<xref ref-type="bibr" rid="article-17697.r28">[28]</xref></p>
        <p><bold>Hydralazine</bold>&#x000a0;can be added to a regimen to treat resistant hypertension, either alone or in combination with nitrates, in case of heart failure.&#x000a0;Hydralazine is associated with increased sympathetic tone and increased sodium avidity; adding a beta-blocker and loop diuretics helps to decrease these effects.<xref ref-type="bibr" rid="article-17697.r9">[9]</xref></p>
        <p><bold>Clonidine</bold>&#x000a0;is a central alpha-2 agonist; it is not a first-line therapy but can be used as an additional agent when the patient fails combination therapy. The transdermal form is preferred.<xref ref-type="bibr" rid="article-17697.r9">[9]</xref></p>
        <p><bold>Minoxidil</bold>&#x000a0;is usually an option when the patient fails treatment with hydralazine.&#x000a0;It usually provides good blood pressure control, but it is associated with fluid retention, for which adding a loop diuretic is helpful. It increases the sympathetic tone that may require adding a beta-blocker.<xref ref-type="bibr" rid="article-17697.r9">[9]</xref>&#x000a0;</p>
        <p><bold>Alpha-blockers</bold>&#x000a0;should not be used to treat hypertension as a first-line agent because they are less effective in preventing cardiovascular disease than other first-line agents.<xref ref-type="bibr" rid="article-17697.r6">[6]</xref></p>
      </sec>
      <sec id="article-17697.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p><bold>Thiazide and Thiazide like diuretics:&#x000a0;</bold>mechanism of action for thiazide-type diuretics is not fully understood.&#x000a0;Thiazides inhibit sodium transport in the distal tubule by blocking the Na/Cl channels.<xref ref-type="bibr" rid="article-17697.r29">[29]</xref>&#x000a0;Thiazides can have a small effect on the proximal tube by impairing sodium transport, but the main action is on the distal tubule. Thiazides cause initial volume depletion associated with decreased cardiac output, which recovers within 6 to 8 weeks of starting the treatment in a reverse autoregulation mechanism while the blood pressure remains controlled; thiazide diuretics can acutely activate the renin-angiotensin system and cause systemic vascular resistance, which prevents a good response to the diuretic treatment, this increase in renin-angiotensin activity may resolve with chronic thiazide treatment, the addition of an ACE inhibitor or ARB can enhance the blood pressure control.&#x000a0;Also, the thiazide-type diuretics have a modest vasodilation effect, although the mechanism is still unclear.</p>
        <p><bold>Calcium channel blockers:&#x000a0;The </bold>mechanism of action of CCBs is related to the inhibition of Ca2+ entry to the cells; this occurs by binding to the L-type voltage-gated calcium channels located in the heart muscle.&#x000a0;This effect can cause peripheral vasodilation, which is seen mainly in dihydropyridines, or a negative inotropic effect on the heart muscle in non-dihydropyridines, inhibiting the sinoatrial and atrioventricular nodes, leading to slow cardiac contractility and conduction.<xref ref-type="bibr" rid="article-17697.r30">[30]</xref></p>
        <p><bold>ACE inhibitors&#x000a0;</bold>decrease blood pressure by inhibiting the angiotensin-converting enzyme; this causes a decline in the production of angiotensin II and increases the bradykinin level by inhibiting its degeneration,&#x000a0;which leads to vasodilation.<xref ref-type="bibr" rid="article-17697.r31">[31]</xref></p>
        <p><bold>ARBs&#x000a0;</bold>work by blocking the binding of angiotensin II to the angiotensin 1 AT1 receptors, which inhibit the angiotensin II effect. In contrast to ACE inhibitors, ARBs do not affect the kinin levels.</p>
        <p><bold>Beta-blockers</bold>&#x000a0;work by inhibiting the catecholamines from binding to the Beta 1, 2, and 3 receptors. Beta-1 receptors are found primarily in the heart muscle, beta-2 receptors are located in the bronchial and peripheral vascular smooth muscles, and beta-3 receptors appear in the adipose tissue of the heart. Cardio-selective beta-blockers (e.g., metoprolol succinate, metoprolol tartrate, atenolol, betaxolol, and acebutolol) inhibit only beta-1 receptors, causing fewer bronchospasms. By inhibiting the catecholamines binding to the beta receptors, the beta-blockers have a negative inotropic effect, which results in a decrease in the heart rate, which helps to reduce oxygen consumption.<xref ref-type="bibr" rid="article-17697.r32">[32]</xref></p>
        <p><bold>Loop diuretics</bold>&#x000a0;work by increasing the sodium exertion at the level of the medullary and cortical aspects of the thick ascending limb. This action causes a decrease in volume, which leads to decreased blood pressure.<xref ref-type="bibr" rid="article-17697.r24">[24]</xref>&#x000a0;&#x000a0;</p>
        <p><bold>Potassium Sparing Diuretics:&#x000a0;&#x000a0;</bold>Act on the principal cells in the late distal tubule and the collecting duct; they inhibit sodium reabsorption at this level in association with decreased excretion of potassium and hydrogen ions.<bold>&#x000a0;</bold>Spironolactone and eplerenone<bold>&#x000a0;</bold>are considered mineralocorticoid receptor antagonists, inhibiting&#x000a0;the mineralocorticoid receptor.</p>
        <p><bold>Hydralazine</bold>&#x000a0;is an arteriolar vasodilator; it inhibits Ca2+ release in the smooth muscles of the vessels by decreasing its cytoplasmic concentration.<xref ref-type="bibr" rid="article-17697.r33">[33]</xref></p>
        <p><bold>Clonidine</bold>&#x000a0;stimulates alpha-2 receptors located in the rostral ventrolateral medulla, which reduces the sympathetic outflow from the central nervous system and decreases plasma norepinephrine levels, leading to decreased cardiac output.</p>
        <p><bold>Minoxidil</bold>&#x000a0;is an arteriolar vasodilator; it opens the adenosine triphosphate-sensitive potassium channels in the vessels' smooth muscles.</p>
        <p><bold>Alpha-blockers&#x000a0;</bold>act by inhibiting alpha-1 receptors, which decrease vascular smooth muscle contractions, leading to vasodilation.<xref ref-type="bibr" rid="article-17697.r34">[34]</xref></p>
      </sec>
      <sec id="article-17697.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Thiazide-type diuretics are given only as oral forms. Hydrochlorothiazide is available in 12.5 and 25 mg tablets, but the daily dose can be up to 50 mg daily.&#x000a0;Chlorthalidone is available in 25 and 50 mg tablets, but the daily dose can be up to 100 mg daily.<xref ref-type="bibr" rid="article-17697.r29">[29]</xref></p>
        <p>Dihydropyridine calcium channel blockers are administered orally. Amlodipine's maximum dose is 10 mg daily.<xref ref-type="bibr" rid="article-17697.r35">[35]</xref>&#x000a0;Nifedipine's extended-release maximum dose is 120 mg daily.<xref ref-type="bibr" rid="article-17697.r36">[36]</xref>&#x000a0;Non-dihydropyridine CCBs are available in oral and intravenous forms; the diltiazem intravenous IV form is useful for heart rate control in cardiac arrhythmias.<xref ref-type="bibr" rid="article-17697.r37">[37]</xref>&#x000a0;The maximum oral dose of diltiazem is 480 mg daily.<xref ref-type="bibr" rid="article-17697.r37">[37]</xref>&#x000a0;Verapamil is available in oral and IV forms as well. The IV form is used for tachyarrhythmias, especially atrial fibrillation.&#x000a0;Oral verapamil dose can be up to a maximum of 480 mg daily.<xref ref-type="bibr" rid="article-17697.r38">[38]</xref>&#x000a0;</p>
        <p>All ACE inhibitors are given orally; enalapril is the only exception, as it has an IV form.<xref ref-type="bibr" rid="article-17697.r31">[31]</xref>&#x000a0;On the other hand, all ARBs are only oral dose forms.<xref ref-type="bibr" rid="article-17697.r39">[39]</xref></p>
        <p>Beta-blockers are available in oral and IV forms.<xref ref-type="bibr" rid="article-17697.r32">[32]</xref>&#x000a0;Loop diuretics are available in oral or IV forms,&#x000a0;while potassium-sparing diuretics are used mainly in oral forms.<xref ref-type="bibr" rid="article-17697.r24">[24]</xref></p>
        <p>Hydralazine administration can be oral or intravenous.&#x000a0;The maximum hydralazine oral dose is 300 mg daily.<xref ref-type="bibr" rid="article-17697.r33">[33]</xref>&#x000a0;</p>
        <p>Clonidine transdermal form is the preferred method of administration, as oral forms can increase the risk of rebound hypertension.<xref ref-type="bibr" rid="article-17697.r9">[9]</xref>&#x000a0;The maximum transdermal clonidine dose is 0.3 mg weekly, while the oral immediate-release form maximum dose is 0.3 mg three times daily.<xref ref-type="bibr" rid="article-17697.r40">[40]</xref>&#x000a0;</p>
        <p>Minoxidil is given orally for hypertension treatment. Alpha-blockers are available only orally for hypertension treatment.<xref ref-type="bibr" rid="article-17697.r41">[41]</xref></p>
      </sec>
      <sec id="article-17697.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Thiazides Side Effects</bold>
</p>
        <p>Thiazide and thiazide-like diuretics are associated with multiple side effects. Most of these side effects are directly related to the diuretic dose; hypokalemia and hyponatremia&#x000a0;are the most common metabolic effects, followed by hyperuricemia, hypomagnesemia, hyperlipidemia, and increased glucose levels.<xref ref-type="bibr" rid="article-17697.r42">[42]</xref><xref ref-type="bibr" rid="article-17697.r29">[29]</xref>&#x000a0;</p>
        <p>Chlorthalidone was found in a study to have an increased risk of hospitalization due to severe hypokalemia in older people. Other non-dose-related side effects are sexual dysfunction and sleep disturbance.</p>
        <p>
<bold>CCB Side Effects</bold>
</p>
        <p>The treatment with dihydropyridine CCBs is often associated with peripheral edema. Long-acting nifedipine is associated with a higher incidence of edema when compared to amlodipine; the edema is related to the dose of the CCB. It is not related to sodium or fluid retention or developing heart failure.<xref ref-type="bibr" rid="article-17697.r9">[9]</xref> Since CCB-induced edema is not a result of volume increase, it does not improve with diuretics therapy; on the other hand, the combination of CCBs with ACE inhibitors or ARBs to a lesser effect showed a decreased risk of developing peripheral edema.&#x000a0;Dihydropyridines can cause lightheadedness, flushing, headaches, and gingival hyperplasia.<xref ref-type="bibr" rid="article-17697.r30">[30]</xref></p>
        <p>Non-dihydropyridines are associated with bradycardia and can cause constipation in 25% of patients.</p>
        <p>CCBs inhibit platelet aggregation and are associated with an increased risk of gastrointestinal bleeding; caution is necessary when prescribing these agents to older patients and patients with a high risk of bleeding.</p>
        <p>
<bold>ACE Is and ARBs Side Effects</bold>
</p>
        <p>The most common side effects related to ACE inhibitors are cough, hypotension, fatigue, and azotemia; reversible renal impairment is a common side effect, especially if the patient develops volume depletion due to diarrhea or vomiting.</p>
        <p>Cough can occur in up to 20% of patients on ACE inhibitors. It takes up to 14&#x000a0;to 28 days after discontinuation for the cough to resolve. The incidence of cough is less common with ARB treatment; comparing losartan with hydrochlorothiazide showed a similar incidence in both medications. ARBs are safe to use in asthma patients; candesartan did not correlate with an increase in the incidence of cough in patients with asthma compared&#x000a0;to CCBs. Ramipril demonstrated a higher rate of cough incidence compared to telmisartan.<xref ref-type="bibr" rid="article-17697.r14">[14]</xref></p>
        <p>ACE inhibitor treatment is commonly associated with mild hyperkalemia. Even in patients with normal renal function, the risk of hyperkalemia increases in patients with renal failure, diabetes, or CHF.<xref ref-type="bibr" rid="article-17697.r43">[43]</xref>&#x000a0;Ramipril and telmisartan are similar in rates of developing hyperkalemia, acute kidney injury, and syncope. Telmisartan is associated with more incidence of symptomatic hypotension.<xref ref-type="bibr" rid="article-17697.r14">[14]</xref></p>
        <p>Angioedema is a rare side effect of ACE inhibitors; it appears in 0.3 % of patients on ramipril. ARBs are less associated with angioedema than ACE inhibitors.<xref ref-type="bibr" rid="article-17697.r14">[14]</xref></p>
        <p>In Black patients, ARBs correlated with less incidence of both cough and angioedema.<xref ref-type="bibr" rid="article-17697.r6">[6]</xref></p>
        <p><bold>Beta-blockers:&#x000a0;</bold>Common side effects of beta-blockers are bradycardia, constipation, depression, fatigue, and sexual dysfunction. Additionally, they are associated with bronchospasm and worsening symptoms of peripheral vascular disease. They can cause a flare-up of Raynaud syndrome.<xref ref-type="bibr" rid="article-17697.r32">[32]</xref></p>
        <p><bold>Loop diuretics:&#x000a0;</bold>are associated with electrolyte imbalance, mainly hypokalemia, hyponatremia, hypomagnesemia, and hypochloremia.<xref ref-type="bibr" rid="article-17697.r24">[24]</xref>&#x000a0;Other metabolic adverse reactions are dehydration, hyperuricemia, and hyperlipidemia.&#x000a0;Ototoxicity and deafness may occur with loop diuretics treatment.<xref ref-type="bibr" rid="article-17697.r25">[25]</xref></p>
        <p><bold>Side effects of the Mineralocorticoid receptor antagonists:</bold>&#x000a0;Hyperkalemia is the major side effect of this group of medications. They can cause metabolic acidosis due to decreased exertion of hydrogen ions. Erectile dysfunction and gynecomastia in men and irregular menstrual periods in women can also occur.<xref ref-type="bibr" rid="article-17697.r9">[9]</xref>&#x000a0;&#x000a0;</p>
        <p><bold>Hydralazine:&#x000a0;</bold>can cause headaches, flushing, palpitations, dizziness, hypotension symptoms, and dizziness due to sympathetic system stimulation.<xref ref-type="bibr" rid="article-17697.r33">[33]</xref>&#x000a0;It is associated with drug-induced lupus erythematosus, hemolytic anemia, and other immune phenomena.<xref ref-type="bibr" rid="article-17697.r33">[33]</xref></p>
        <p><bold>Clonidine's&#x000a0;</bold>common side effects are drowsiness, headache, dizziness, irritability, nausea and vomiting, constipation, upper abdominal pain, and bradycardia, but other serious side effects can occur as angioedema, atrioventricular block, and severe hypotension.<xref ref-type="bibr" rid="article-17697.r40">[40]</xref></p>
        <p><bold>Minoxidil</bold>&#x000a0;is associated with hirsutism.<xref ref-type="bibr" rid="article-17697.r44">[44]</xref></p>
        <p><bold>Alpha-blockers&#x000a0;</bold>are associated with tachycardia and orthostatic hypotension as a result of venous dilation.<xref ref-type="bibr" rid="article-17697.r34">[34]</xref></p>
      </sec>
      <sec id="article-17697.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Thiazide type diuretics are contraindicated if the patient is anuric, and in patients with sulfonamide allergies.<xref ref-type="bibr" rid="article-17697.r29">[29]</xref></p>
        <p>CCBs are contraindicated in patients with hypersensitivity to the drug.<xref ref-type="bibr" rid="article-17697.r30">[30]</xref>&#x000a0;Non-dihydropyridine contraindications include patients with heart failure, reduced ejection fraction, sick sinus syndrome, and second or third-degree AV blockade.<xref ref-type="bibr" rid="article-17697.r30">[30]</xref>&#x000a0;Dihydropyridine should be avoided in cardiogenic shock patients, severe aortic stenosis, and unstable angina; special caution is necessary when dihydropyridine is useful in hepatic impaired patients.<xref ref-type="bibr" rid="article-17697.r36">[36]</xref><xref ref-type="bibr" rid="article-17697.r35">[35]</xref></p>
        <p>ACE inhibitors are contraindicated in patients with a history of previous hypersensitivity to ACE inhibitors, a history of ACE inhibitor-related angioedema, other types of angioedema, pregnancy, or the use of aliskiren.<xref ref-type="bibr" rid="article-17697.r45">[45]</xref>&#x000a0;Relative contraindications include patients with volume depletion, abnormal renal function, and aortic valve stenosis.<xref ref-type="bibr" rid="article-17697.r45">[45]</xref>&#x000a0;ARBs are contraindicated in pregnancy.<xref ref-type="bibr" rid="article-17697.r39">[39]</xref>&#x000a0;A combination of ACE inhibitors and ARBs is relatively contraindicated. Other relative contraindications for ARB treatment include patients with volume depletion, patients on other medications that cause hyperkalemia,&#x000a0;or patients with abnormal renal function.<xref ref-type="bibr" rid="article-17697.r39">[39]</xref></p>
        <p>Beta-blockers are contraindicated in patients with asthma, especially nonselective beta-blockers.&#x000a0;Relative contraindications are hypotension and bradycardia. Some feel they should be avoided in patients with cocaine-induced coronary artery spasms.<xref ref-type="bibr" rid="article-17697.r32">[32]</xref></p>
        <p>Loop diuretics are contraindicated in patients with hypersensitivity to sulfonamides, anuric patients, and patients with hepatic coma.<xref ref-type="bibr" rid="article-17697.r24">[24]</xref></p>
        <p>Potassium-sparing diuretics are contraindicated in patients with chronic kidney disease or hyperkalemia; caution is necessary when combining them with ACE inhibitors, ARBs, and aliskiren.<xref ref-type="bibr" rid="article-17697.r46">[46]</xref>&#x000a0;They are contraindicated in patients with hypersensitivity to this class.</p>
        <p>&#x000a0;Clonidine is contraindicated in patients with hypersensitivity to alpha-2 agonists&#x000a0;and should be avoided in patients with depression and recent myocardial infarctions.<xref ref-type="bibr" rid="article-17697.r40">[40]</xref></p>
        <p>Hydralazine is contraindicated if the patient has a history of hydralazine allergy. In patients with coronary artery disease, hydralazine can stimulate the sympathetic system.&#x000a0;In patients with rheumatic mitral valve disease, pulmonary artery pressure can increase due to hydralazine treatment.<xref ref-type="bibr" rid="article-17697.r47">[47]</xref><xref ref-type="bibr" rid="article-17697.r33">[33]</xref></p>
        <p>Minoxidil is contraindicated in pregnant and breastfeeding females and patients with hypersensitivity to minoxidil.<xref ref-type="bibr" rid="article-17697.r44">[44]</xref></p>
        <p>Contraindications to alpha-blockers include patients with a history of orthostatic hypotension and patients on phosphodiesterase inhibitors.<xref ref-type="bibr" rid="article-17697.r41">[41]</xref></p>
      </sec>
      <sec id="article-17697.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Thiazides<bold>&#x000a0;</bold>and loop diuretics can cause hypokalemia, while potassium-sparing diuretics cause hyperkalemia.<xref ref-type="bibr" rid="article-17697.r24">[24]</xref><xref ref-type="bibr" rid="article-17697.r29">[29]</xref> Electrolytes should be monitored in patients on diuretics,&#x000a0;and uric acid monitoring is recommended in patients on thiazides and loop diuretics.<xref ref-type="bibr" rid="article-17697.r24">[24]</xref><xref ref-type="bibr" rid="article-17697.r46">[46]</xref> Monitoring for ototoxicity and deafness should be considered in patients on loop diuretics.<xref ref-type="bibr" rid="article-17697.r24">[24]</xref></p>
        <p>Hyperkalemia is common in ACE inhibitor and ARB treatment, and special caution is required when combining these agents with potassium-sparing diuretics.&#x000a0;Potassium levels should be closely monitored in patients with chronic kidney disease when ACE inhibitors, ARBs,&#x000a0;or potassium-sparing diuretics are used.<xref ref-type="bibr" rid="article-17697.r39">[39]</xref> ACE inhibitors and ARBs can cause acute kidney injury, and renal function requires monitoring.<xref ref-type="bibr" rid="article-17697.r45">[45]</xref><xref ref-type="bibr" rid="article-17697.r39">[39]</xref></p>
        <p>Monitoring for hypotension and edema is necessary for patients on dihydropyridine CCBs. Non-dihydropyridine CCBs and beta-blockers are known to cause bradycardia, and heart rate requires monitoring,&#x000a0;especially if these two medications are combined. QTc interval needs monitoring in patients on sotalol.<xref ref-type="bibr" rid="article-17697.r30">[30]</xref><xref ref-type="bibr" rid="article-17697.r32">[32]</xref></p>
        <p>Monitoring for tachyarrhythmias and orthostatic hypotension is a recommendation in patients on alpha-blockers.<xref ref-type="bibr" rid="article-17697.r34">[34]</xref><xref ref-type="bibr" rid="article-17697.r41">[41]</xref></p>
        <p>Complete blood count and ANA levels are advisable for monitoring when the patient is on hydralazine treatment.<xref ref-type="bibr" rid="article-17697.r33">[33]</xref>&#x000a0;Special caution is necessary if patients develop arthralgia, fever, or other systemic symptoms.<xref ref-type="bibr" rid="article-17697.r48">[48]</xref></p>
      </sec>
      <sec id="article-17697.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Thiazides and loop diuretics toxicity can cause electrolyte abnormalities ( mainly hypokalemia and hyponatremia) and metabolic acidosis (hypochloremic). Severe dehydration can occur. No antidotes&#x000a0;are available for these diuretics; treatment is primarily volume and electrolyte replacement.<xref ref-type="bibr" rid="article-17697.r24">[24]</xref></p>
        <p>Potassium-sparing diuretics toxicity presents as severe hyperkalemia; the main treatment is to stop all medications that cause elevated potassium levels, IV hydration, IV calcium gluconate, IV insulin with glucose, sodium bicarbonate, and potassium binding resins.<xref ref-type="bibr" rid="article-17697.r46">[46]</xref></p>
        <p>Non-dihydropyridine CCB toxicity occurs due to the decreased ionotropy effect on the cardiac muscle, leading to bradycardia and hypotension. A complete heart block and idioventricular rhythm can occur.<xref ref-type="bibr" rid="article-17697.r30">[30]</xref>&#x000a0;Dihydropyridine CCBs cause peripheral vasodilation and severe hypotension but have less effect on the heart rate.&#x000a0;IV hydration is recommended for hypotension, IV atropine, and an external pacemaker for bradycardia. Calcium chloride or calcium gluconate intravenously can help hypotension if IV hydration does not improve blood pressure. IV vasopressors can be an option if blood pressure does not improve.<xref ref-type="bibr" rid="article-17697.r30">[30]</xref></p>
        <p>Toxicity from ACE inhibitors and ARBs can cause severe hypotension, hyperkalemia, and hyponatremia.&#x000a0;No antidotes&#x000a0;are available, and IV hydration and management for hyperkalemia are recommended.<xref ref-type="bibr" rid="article-17697.r31">[31]</xref></p>
        <p>Like CCBs, beta-blockers cause hypotension and bradycardia and may lead to second or third-degree AV blocks.&#x000a0;IV glucagon is the initial antidote; IV hydration and an external pacemaker may be required if there is no response.<xref ref-type="bibr" rid="article-17697.r32">[32]</xref>&#x000a0;</p>
        <p>Hydralazine toxicity can cause severe hypotension, tachycardia, and skin flushing; in severe cases, patients may develop cardiac shock or myocardial ischemia.&#x000a0;No antidote is available; IV hydration and IV vasopressors are interventions for severe cases. Beta-blockers can be used for severe tachycardia.<xref ref-type="bibr" rid="article-17697.r33">[33]</xref></p>
        <p>Clonidine toxicity can present as lethargy, hypotension, bradycardia, and miosis. In severe cases, respiratory depression may develop.&#x000a0;Treatment is supportive care with hydration and vasopressors. Dopamine and norepinephrine are common choices in this scenario.&#x000a0;IV atropine is an option for severe bradycardia, and the use of an external pacemaker is reserved for cases resistant to atropine treatment.<xref ref-type="bibr" rid="article-17697.r49">[49]</xref></p>
        <p>Minoxidil toxicity can cause tachycardia and hypotension. Treatment is supportive with IV hydration and vasopressors.<xref ref-type="bibr" rid="article-17697.r44">[44]</xref></p>
        <p>Alpha-blockers toxicity can cause severe hypotension, and IV hydration and vasopressors are the primary treatment options.<xref ref-type="bibr" rid="article-17697.r50">[50]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-17697.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Antihypertensives are a broad group of medications, and healthcare workers are recommended to have special caution in monitoring adherence and possible adverse reactions to these medications. Treatment of HTN is essential in preventing cardiovascular disease, and choosing the precise class of drugs is critical to achieving the appropriate control with fewer side effects.</p>
        <p>An interprofessional team of clinicians, nurses, and pharmacists is required to monitor patients on these medications. The clinician starts the antihypertensive regimen; this should be followed by special attention from the pharmacies to check on the drug-drug interactions, patient adherence to treatment, and medication reconciliation. The nurse plays a vital role in monitoring the patient's adherence and determining barriers to good response to the treatment, including monitoring diet and activity levels and evaluating the home environment. Home visiting nurses will monitor blood pressure and heart rate response to the treatment and identify early adverse reactions. Both pharmacists and nurses should inform the clinician of any possible concerns of adherence, adverse reactions, or home environmental changes. This comprehensive interprofessional team effort helps achieve the maximal benefits of the regimen and the best care delivery to the patient and family. [Level 5]</p>
      </sec>
      <sec id="article-17697.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17697&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17697">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17697/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17697">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17697.s11">
        <title>References</title>
        <ref id="article-17697.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ettehad</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Emdin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Kiran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Callender</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Emberson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chalmers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rahimi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.</article-title>
            <source>Lancet</source>
            <year>2016</year>
            <month>Mar</month>
            <day>05</day>
            <volume>387</volume>
            <issue>10022</issue>
            <fpage>957</fpage>
            <page-range>957-967</page-range>
            <pub-id pub-id-type="pmid">26724178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armstrong</surname>
                <given-names>C</given-names>
              </name>
              <collab>Joint National Committee</collab>
            </person-group>
            <article-title>JNC8 guidelines for the management of hypertension in adults.</article-title>
            <source>Am Fam Physician</source>
            <year>2014</year>
            <month>Oct</month>
            <day>01</day>
            <volume>90</volume>
            <issue>7</issue>
            <fpage>503</fpage>
            <page-range>503-4</page-range>
            <pub-id pub-id-type="pmid">25369633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Messerli</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Bangalore</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark?</article-title>
            <source>Circulation</source>
            <year>2009</year>
            <month>Jan</month>
            <day>27</day>
            <volume>119</volume>
            <issue>3</issue>
            <fpage>371</fpage>
            <page-range>371-3</page-range>
            <pub-id pub-id-type="pmid">19171867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ernst</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Goerdt</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Steffensmeier</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Bergus</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.</article-title>
            <source>Hypertension</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>352</fpage>
            <page-range>352-8</page-range>
            <pub-id pub-id-type="pmid">16432050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olde Engberink</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Frenkel</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>van den Bogaard</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brewster</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Vogt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>van den Born</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis.</article-title>
            <source>Hypertension</source>
            <year>2015</year>
            <month>May</month>
            <volume>65</volume>
            <issue>5</issue>
            <fpage>1033</fpage>
            <page-range>1033-40</page-range>
            <pub-id pub-id-type="pmid">25733241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>e13</fpage>
            <page-range>e13-e115</page-range>
            <pub-id pub-id-type="pmid">29133356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Chlorthalidone versus hydrochlorothiazide: a tale of tortoises and a hare.</article-title>
            <source>Hypertension</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>58</volume>
            <issue>6</issue>
            <fpage>994</fpage>
            <page-range>994-5</page-range>
            <pub-id pub-id-type="pmid">22025371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finkielman</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Boerwinkle</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide.</article-title>
            <source>Am J Hypertens</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>398</fpage>
            <page-range>398-402</page-range>
            <pub-id pub-id-type="pmid">15797660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Calhoun</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Brook</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Daugherty</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Dennison-Himmelfarb</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Egan</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Flack</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Judd</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lackland</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Laffer</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Newton-Cheh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Textor</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Turan</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>WB</given-names>
              </name>
              <collab>American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council</collab>
            </person-group>
            <article-title>Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>72</volume>
            <issue>5</issue>
            <fpage>e53</fpage>
            <page-range>e53-e90</page-range>
            <pub-id pub-id-type="pmid">30354828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puttnam</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Pressel</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Louis</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Margolis</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Oparil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Einhorn</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Barzilay</surname>
                <given-names>JI</given-names>
              </name>
              <collab>Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group</collab>
            </person-group>
            <article-title>Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial.</article-title>
            <source>JAMA Intern Med</source>
            <year>2017</year>
            <month>Jan</month>
            <day>01</day>
            <volume>177</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-76</page-range>
            <pub-id pub-id-type="pmid">27893045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Probstfield</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Pressel</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Cutler</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Einhorn</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Haywood</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Margolis</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Oparil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Alderman</surname>
                <given-names>MH</given-names>
              </name>
              <collab>ALLHAT Collaborative Research Group</collab>
            </person-group>
            <article-title>ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.</article-title>
            <source>Arch Intern Med</source>
            <year>2009</year>
            <month>May</month>
            <day>11</day>
            <volume>169</volume>
            <issue>9</issue>
            <fpage>832</fpage>
            <page-range>832-42</page-range>
            <pub-id pub-id-type="pmid">19433694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dahl&#x000f6;f</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sever</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Poulter</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Wedel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Beevers</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Caulfield</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kristinsson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McInnes</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Mehlsen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nieminen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ostergren</surname>
                <given-names>J</given-names>
              </name>
              <collab>ASCOT Investigators</collab>
            </person-group>
            <article-title>Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.</article-title>
            <source>Lancet</source>
            <year>2005</year>
            <month>Sep</month>
            <day>10-16</day>
            <volume>366</volume>
            <issue>9489</issue>
            <fpage>895</fpage>
            <page-range>895-906</page-range>
            <pub-id pub-id-type="pmid">16154016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weber</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Weir</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Zappe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dahlof</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Velazquez</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.</article-title>
            <source>Lancet</source>
            <year>2013</year>
            <month>Feb</month>
            <day>16</day>
            <volume>381</volume>
            <issue>9866</issue>
            <fpage>537</fpage>
            <page-range>537-45</page-range>
            <pub-id pub-id-type="pmid">23219284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>ONTARGET Investigators</collab>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Teo</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Pogue</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dyal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Copland</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dagenais</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sleight</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Telmisartan, ramipril, or both in patients at high risk for vascular events.</article-title>
            <source>N Engl J Med</source>
            <year>2008</year>
            <month>Apr</month>
            <day>10</day>
            <volume>358</volume>
            <issue>15</issue>
            <fpage>1547</fpage>
            <page-range>1547-59</page-range>
            <pub-id pub-id-type="pmid">18378520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>McAlister</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis.</article-title>
            <source>CMAJ</source>
            <year>2006</year>
            <month>Jun</month>
            <day>06</day>
            <volume>174</volume>
            <issue>12</issue>
            <fpage>1737</fpage>
            <page-range>1737-42</page-range>
            <pub-id pub-id-type="pmid">16754904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomopoulos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Parati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zanchetti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 - effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis.</article-title>
            <source>J Hypertens</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>8</issue>
            <fpage>1637</fpage>
            <page-range>1637-1647</page-range>
            <pub-id pub-id-type="pmid">29847487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindholm</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Carlberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Samuelsson</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis.</article-title>
            <source>Lancet</source>
            <string-date>2005 Oct 29-Nov 4</string-date>
            <volume>366</volume>
            <issue>9496</issue>
            <fpage>1545</fpage>
            <page-range>1545-53</page-range>
            <pub-id pub-id-type="pmid">16257341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wald</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Bestwick</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Wald</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.</article-title>
            <source>Am J Med</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>122</volume>
            <issue>3</issue>
            <fpage>290</fpage>
            <page-range>290-300</page-range>
            <pub-id pub-id-type="pmid">19272490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mancia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Spiering</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Agabiti Rosei</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Azizi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burnier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clement</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Coca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Simone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dominiczak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kahan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mahfoud</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Redon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ruilope</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zanchetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kerins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kreutz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Laurent</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GYH</given-names>
              </name>
              <name>
                <surname>McManus</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Narkiewicz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ruschitzka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schmieder</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Shlyakhto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tsioufis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Aboyans</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Desormais</surname>
                <given-names>I</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2018 ESC/ESH Guidelines for the management of arterial hypertension.</article-title>
            <source>Eur Heart J</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>39</volume>
            <issue>33</issue>
            <fpage>3021</fpage>
            <page-range>3021-3104</page-range>
            <pub-id pub-id-type="pmid">30165516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>James</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Oparil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Dennison-Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Handler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lackland</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>LeFevre</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>MacKenzie</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Ogedegbe</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Svetkey</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Townsend</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Narva</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Ortiz</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).</article-title>
            <source>JAMA</source>
            <year>2014</year>
            <month>Feb</month>
            <day>05</day>
            <volume>311</volume>
            <issue>5</issue>
            <fpage>507</fpage>
            <page-range>507-20</page-range>
            <pub-id pub-id-type="pmid">24352797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jamerson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Dahl&#x000f6;f</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hester</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gupte</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gatlin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Velazquez</surname>
                <given-names>EJ</given-names>
              </name>
              <collab>ACCOMPLISH Trial Investigators</collab>
            </person-group>
            <article-title>Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.</article-title>
            <source>N Engl J Med</source>
            <year>2008</year>
            <month>Dec</month>
            <day>04</day>
            <volume>359</volume>
            <issue>23</issue>
            <fpage>2417</fpage>
            <page-range>2417-28</page-range>
            <pub-id pub-id-type="pmid">19052124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakris</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Sarafidis</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Weir</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Dahl&#x000f6;f</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Velazquez</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Staikos-Byrne</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>MA</given-names>
              </name>
              <collab>ACCOMPLISH Trial investigators</collab>
            </person-group>
            <article-title>Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.</article-title>
            <source>Lancet</source>
            <year>2010</year>
            <month>Apr</month>
            <day>03</day>
            <volume>375</volume>
            <issue>9721</issue>
            <fpage>1173</fpage>
            <page-range>1173-81</page-range>
            <pub-id pub-id-type="pmid">20170948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phillips</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Kashani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.</article-title>
            <source>Arch Intern Med</source>
            <year>2007</year>
            <month>Oct</month>
            <day>08</day>
            <volume>167</volume>
            <issue>18</issue>
            <fpage>1930</fpage>
            <page-range>1930-6</page-range>
            <pub-id pub-id-type="pmid">17923591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Huxel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Raja</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ollivierre-Lawrence</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <chapter-title>Loop Diuretics</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">31536262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sica</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Thiazide and loop diuretics.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>639</fpage>
            <page-range>639-43</page-range>
            <pub-id pub-id-type="pmid">21896142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chapman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dobson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dahl&#x000f6;f</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sever</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Wedel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Poulter</surname>
                <given-names>NR</given-names>
              </name>
              <collab>Anglo-Scandinavian Cardiac Outcomes Trial Investigators</collab>
            </person-group>
            <article-title>Effect of spironolactone on blood pressure in subjects with resistant hypertension.</article-title>
            <source>Hypertension</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>49</volume>
            <issue>4</issue>
            <fpage>839</fpage>
            <page-range>839-45</page-range>
            <pub-id pub-id-type="pmid">17309946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khosla</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kalaitzidis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bakris</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.</article-title>
            <source>Am J Nephrol</source>
            <year>2009</year>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>418</fpage>
            <page-range>418-24</page-range>
            <pub-id pub-id-type="pmid">19738369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Morant</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Sever</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McInnes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cruickshank</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Caulfield</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Salsbury</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mackenzie</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Padmanabhan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>MJ</given-names>
              </name>
              <collab>British Hypertension Society's PATHWAY Studies Group</collab>
            </person-group>
            <article-title>Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.</article-title>
            <source>Lancet</source>
            <year>2015</year>
            <month>Nov</month>
            <day>21</day>
            <volume>386</volume>
            <issue>10008</issue>
            <fpage>2059</fpage>
            <page-range>2059-2068</page-range>
            <pub-id pub-id-type="pmid">26414968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r29">
          <label>29</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Akbari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Khorasani-Zadeh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Thiazide Diuretics</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">30422513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r30">
          <label>30</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>McKeever</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <chapter-title>Calcium Channel Blockers</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>8</month>
            <day>5</day>
            <pub-id pub-id-type="pmid">29494080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r31">
          <label>31</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Herman</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Padala</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bashir</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Angiotensin-Converting Enzyme Inhibitors (ACEI)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">28613705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r32">
          <label>32</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Farzam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Beta Blockers</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">30422501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r33">
          <label>33</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Herman</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Bruss</surname>
                <given-names>ZS</given-names>
              </name>
              <name>
                <surname>Tivakaran</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <chapter-title>Hydralazine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">29262006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r34">
          <label>34</label>
          <element-citation publication-type="book">
            <chapter-title>Alpha 1 Adrenergic Receptor Antagonists</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>1</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">31644028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r35">
          <label>35</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bulsara</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Cassagnol</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Amlodipine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">30137793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r36">
          <label>36</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Khan</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <chapter-title>Nifedipine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">30725737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r37">
          <label>37</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Talreja</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cassagnol</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Diltiazem</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">30422532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r38">
          <label>38</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Fahie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cassagnol</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Verapamil</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">30860730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r39">
          <label>39</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Hill</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Vaidya</surname>
                <given-names>PN</given-names>
              </name>
            </person-group>
            <chapter-title>Angiotensin II Receptor Blockers (ARB)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">30725712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r40">
          <label>40</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Yasaei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saadabadi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Clonidine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">29083638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r41">
          <label>41</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Taylor</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Cassagnol</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Alpha-Adrenergic Receptors</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">30969652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pazo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Karson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Risk of thiazide-induced hyponatremia in patients with hypertension.</article-title>
            <source>Am J Med</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>124</volume>
            <issue>11</issue>
            <fpage>1064</fpage>
            <page-range>1064-72</page-range>
            <pub-id pub-id-type="pmid">22017784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desai</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Swedberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Dunlap</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Hainer</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Olofsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Michelson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <collab>CHARM Program Investigators</collab>
            </person-group>
            <article-title>Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2007</year>
            <month>Nov</month>
            <day>13</day>
            <volume>50</volume>
            <issue>20</issue>
            <fpage>1959</fpage>
            <page-range>1959-66</page-range>
            <pub-id pub-id-type="pmid">17996561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r44">
          <label>44</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nessel</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Kumar D</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <chapter-title>Minoxidil</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>12</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">29494000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r45">
          <label>45</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Goyal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cusick</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Thielemier</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <chapter-title>ACE Inhibitors</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">28613646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r46">
          <label>46</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Almajid</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Cassagnol</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Amiloride</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>10</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31194443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kandler</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Mah</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Tejani</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Stabler</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Salzwedel</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Hydralazine for essential hypertension.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2011</year>
            <month>Nov</month>
            <day>09</day>
            <issue>11</issue>
            <fpage>CD004934</fpage>
            <pub-id pub-id-type="pmid">22071816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iyer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dirweesh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zijoo</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Hydralazine Induced Lupus Syndrome Presenting with Recurrent Pericardial Effusion and a Negative Antinuclear Antibody.</article-title>
            <source>Case Rep Rheumatol</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>5245904</fpage>
            <pub-id pub-id-type="pmid">28194293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r49">
          <label>49</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Manzon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nappe</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>DelMaestro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maguire</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <chapter-title>Clonidine Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">29083752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17697.r50">
          <label>50</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Yang</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Raja</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Terazosin</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">31424792</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
